And since programmed cell death protein-1 (PD-1) inhibitors are currently considered as one of the most promising treatments for HCC, and their efficacy varies widely among individuals, patients treated with anti-PD-1 therapy were also compared in our study. Here, PDCD1 is linked to hepatocellular carcinoma.